The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Managing TP53-mutated MDS: current strategies and remaining therapeutic challenges
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares insights into managing patients with TP53-mutated myelodysplastic syndromes (MDS) and remaining therapeutic challenges. Dr Cluzeau notes that the current standard of care includes azacitidine and consideration of stem cell transplantation; however, poor patient outcomes persist, necessitating further clinical research. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Today, as you know, the TP53 mutated MDS are very poor, very poor outcome. So today we continue to treat this patient with azacitidine and if by chance, if we obtain a response and if the patient is eligible to allow stem cell transplantation, we try to transplant this patient. We discuss also to use after transplant a maintenance treatment using azacitidine or azacitidine plus DLI in prophylactics as prophylactic treatment because we know this patient relapse...
Today, as you know, the TP53 mutated MDS are very poor, very poor outcome. So today we continue to treat this patient with azacitidine and if by chance, if we obtain a response and if the patient is eligible to allow stem cell transplantation, we try to transplant this patient. We discuss also to use after transplant a maintenance treatment using azacitidine or azacitidine plus DLI in prophylactics as prophylactic treatment because we know this patient relapse. So this is the standard of care for today for this patient. But unfortunately, if there is no transplant, the median overall survival of the patient stays around six to nine months. So we try to design some clinical trials to improve the outcome of this patient. And with the French group of myelodysplasia we designed some clinical trials and we hope to open some clinical trials very soon in first line but also in second line in a relapsed/refractory setting and we hope maybe to improve the outcome of this patient.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
